Chemist + Druggist is part of Pharma Intelligence UK Limited
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Having Problems? Get in Touch
This copy is for your personal, non-commercial use. Please do not redistribute without permission.
Printed By
The Competition Appeal Tribunal (CAT) has quashed an appeal by Advanz Pharma, Cinven and HgCapital against the market watchdog’s findings on “excessive” pricing of liothyronine.
In a “landmark judgment”, the CAT has ruled in favour of the Competition and Markets Authority’s (CMA) July 2021 decision to fine Advanz Pharma and
| Table |
|---|
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
